Subscribe
360b-shutterstock-com-16
360b / Shutterstock.com
12 February 2016Africa

GSK fined £37m for ‘anti-competitive’ conduct

GSK has been fined more than £37 million ($53 million) by the UK government for “anti-competitive conduct” in relation to ‘pay for delay’ deals centring on anti-depressant drug Seroxat (paroxetine).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
GSK’s Seroxat pay-for-delay deals may restrict competition: AG
23 January 2020   GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union.
Africa
GSK to widen access to medicines in world’s poorest countries
1 April 2016   Pharmaceutical company GSK has adopted a new approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
GSK’s Seroxat pay-for-delay deals may restrict competition: AG
23 January 2020   GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union.
Africa
GSK to widen access to medicines in world’s poorest countries
1 April 2016   Pharmaceutical company GSK has adopted a new approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.

More on this story

Big Pharma
GSK’s Seroxat pay-for-delay deals may restrict competition: AG
23 January 2020   GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union.
Africa
GSK to widen access to medicines in world’s poorest countries
1 April 2016   Pharmaceutical company GSK has adopted a new approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims